Literature DB >> 23246385

Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients.

Stavros Apostolakis, Deirdre A Lane, Yutao Guo, Harry Buller, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23246385     DOI： 10.1016/j.jacc.2012.10.010

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  20 in total

1.  The clinical utility of imaging-defined biotypes of depression and transcranial magnetic stimulation: A decision curve analysis.

Authors:  Yosef A Berlow; Amin Zandvakili; Noah S Philip
Journal:  Brain Stimul       Date:  2020-04-28       Impact factor: 8.955

2.  Validation Of The HAS-BLED Tool In Atrial Fibrillation Patients Receiving Rivaroxaban.

Authors:  E W Gorman; D Perkel; D Dennis; J Yates; R E Heidel; D Wortham
Journal:  J Atr Fibrillation       Date:  2016-08-31

Review 3.  Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making.

Authors:  Yishen Wang; Beata Bajorek
Journal:  Ther Adv Drug Saf       Date:  2014-02

Review 4.  Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis.

Authors:  Daniel Caldeira; João Costa; Ricardo M Fernandes; Fausto J Pinto; Joaquim J Ferreira
Journal:  J Interv Card Electrophysiol       Date:  2014-07-11       Impact factor: 1.900

Review 5.  Cerebral Microhemorrhages: Significance, Associations, Diagnosis, and Treatment.

Authors:  Eric Jouvent; Laurent Puy; Hugues Chabriat
Journal:  Curr Treat Options Neurol       Date:  2016-08       Impact factor: 3.598

6.  A standardized bleeding risk score aligns anticoagulation choices with current evidence.

Authors:  Arielle S Berger; Andrew S Dunn; Amy S Kelley
Journal:  Crit Pathw Cardiol       Date:  2014-09

Review 7.  Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting.

Authors:  Anne-Sophie Dincq; Sarah Lessire; Jonathan Douxfils; Jean-Michel Dogné; Maximilien Gourdin; François Mullier
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

8.  The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.

Authors:  Emily C O'Brien; DaJuanicia N Simon; Laine E Thomas; Elaine M Hylek; Bernard J Gersh; Jack E Ansell; Peter R Kowey; Kenneth W Mahaffey; Paul Chang; Gregg C Fonarow; Michael J Pencina; Jonathan P Piccini; Eric D Peterson
Journal:  Eur Heart J       Date:  2015-09-29       Impact factor: 29.983

9.  Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy.

Authors:  Chinmay G Deshpande; Stephen Kogut; Cynthia Willey
Journal:  J Manag Care Spec Pharm       Date:  2018-05

10.  Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.

Authors:  Marco Proietti; Keitaro Senoo; Deirdre A Lane; Gregory Y H Lip
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.